Member Info for Hulver

(i) to set current context and focus to the report, which is otherwise bias to 2023 and the 31/12/23 position and required disclosures; and

(ii) it's a continuation of the much improved and welcome engagement with shareholders (as a whole) that we started to see in 2023, and this is re-emphasised on page 31 of the Annual Report (but to save people reading teh report to find it):

"The Company is committed to a continuous dialogue with shareholders as it believes that this is essential to ensure a greater understanding of and confidence amongst its shareholders in the medium- and longer- term strategy of the Group and in the Board’s ability to oversee its implementation. It is the responsibility of the Board as a whole to ensure that a satisfactory dialogue takes place."

That said, (as many others have stated they have found previously) I also didn't get 'Proof of Concept' for the statement promulgated on p32 of the Annual Report:

"The Board’s primary shareholder contact is through Peter Redmond, the Non-Executive Director responsible for shareholder relations." - as I too didn't get any response or acknowledgement to my emailed request. But I see that he was in attendance at 12/12 board meetings in 2023 - though I'm not sure that's going to get my vote for re-election at this year's AGM - more needed.

An extract from Note 23 of the Financial Statements under Service Agreements:

"In September 2023, Hemogenyx Pharmaceuticals entered into a Master Services and Contract Agreement for a third party to provide clinical services and technologies for the forthcoming Phase I clinical trials for an initial term of 38 months, paying an aggregate of 2,530,057. This includes an upfront payment of 986,713 and monthly instalments over 38 months of 41,712 commencing in April 2024. No sums other than an upfront fee were paid during the year ended 31 December 2023."

- the monthly instalments payments 'commencing April 24' suggests to me that the commencement of the first trial is not that far away now, as Prevail are starting or about to start to undertake the regular work/services to be provided under the contract.

But starting soon ......

HEMO's patients will not be running out of life.

I think there is little doubt that the cash will continue to be raised, when it's needed. The fountain is flowing.

Have to agree with this title, and early release suggests Vlad at the LSX conference in London next week (29th/30th) or more news to come, that they wanted to keep separate (if anything worthy of announcement had happened pre-results release then would have to be lost in the PBSE note to the financials?

Going concern - seemingly not too much of an issue to prove for next 12 months (from signing date)

Perhaps coordinating attendance at this event in London with the board meeting and approval of year end report

https://informaconnect.com/lsx-world-congress/

in any case, looking forward to a more comprehensive update on progress - several CBRs are ready for next stage testing.

Typo - think they meant 'slow grift'

Chris, that's very interesting and I hope you are right. There has been a notable absence of Prevail either in the CH lift RNS nor any of the interviews or other media reports published since. Neither did Prevail issued anything of a congratulatory nature to promote Hemo on the CH lift on their media outlets.

Maybe Hemo board didn't like the way things seem to have gone over at BriaCell Therapeutics since Prevail's invested $4m as lead investor in its funding round. The subsequent spin out of one third of that company's pre-clinical assets, which was proposed prior to the funding round but only approved after, to a new company BriaPro, has seen BriaCell Therapeutics' share price drop from $6 at the time of the funding round (May 23), $7 just prior to the spin-out (Aug 23) down to around $2.15 (today); though the investors would seem to have received shares in BriaPro - but that's an unlisted reporting issuer in Canada.

Awaiting the Annual Report with interest.

Reference to CDX Phase 1 'expected 2025 - 2026' - that's new.

Not sure that all the biographies are current - more people to be added too maybe.

And with a significant additions of CBR constructs to the pipeline.

Two weeks until the annual report update.

Last year they advised that IND enabling studies had been initiated on CDX. Nothing further since then on CDX but a brief comment in video output to suggest work was ongoing and Vlad's comment that he was not expecting HEMO CAR-T to be the company's only IND submission - but was he referring to CDX or one or more CBR constructs (several of which were reported, last September, as having already been developed and ready for next stage testing)?

We are now in the Spring 2024 window for the announcement of New York Biofense Commercialization Fund Grants.

Did HEMO make a short submission; was it then invited to make a full submission - we don't know? But HEMO does seem to fit the application parameters - with its innovative CBR technology?

2022 Award Winners - announced 11 April 2022

2023 Award Winners - announced 4 May 2023

https://www.governor.ny.gov/news/governor-hochul-launches-applications-third-round-new-yorks-40-million-biodefense

Https://www.proactiveinvestors.co.uk/companies/news/1044876/hemogenyx-pharmaceuticals-important-fund-raise-and-car-t-potential-makes-it-one-to-watch-1044876.html

per the Proactive report and UPenn's continued interest/involvement - "all along it has been data driven"

And remember that Hemo had developed a safety switch for SAFE-HEMO-CAR-T but in the end they determined (presumably in the work with UPenn) that due to other scientific advances it was not necessary to have the esafety switch for HEMO CAR-T.

Back to the science:

CD123 CAR-T was previously reported as UPenn's gold standard; here's what happened

https://ashpublications.org/blood/article/142/Supplement%201/217/503095/Cytokine-Release-Syndrome-Results-in-Reduced-AML

Note - one of the authors is Noelle Frey - who will now be the Principal Investigator for HEMO CAR-T Phase I at UPenn.

So - HEMO CAR-T now on pole position for the race to AML solution?

...or at least a stepping stone along the way.

I could not find anything to show he was presenting, so assume just as an attendee.

...and over the weekend Vlad's been attending the 2024 AACR Meeting in San Diego - doing his bit to spread the word about HEMO.

https://www.aacr.org/meeting/aacr-annual-meeting-2024/program/

Https://www.bbc.co.uk/news/av/world-us-canada-68744775

The mice are gathering!

So perhaps the potential PIPE funding round led by Prevail is still in play.

Here you go, captain

https://twitter.com/HemogenyxPharma/status/1776029505905442879?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Etweet